Netcapital to Host Planned Reg A Offering by Algernon NeuroScience
Netcapital Inc. (NASDAQ: NCPL) announced that its subsidiary, Netcapital Securities, will provide broker-dealer and administrative services for Algernon NeuroScience's planned Regulation A offering. The announcement, made on March 07, 2025, excludes underwriting and placement agent services.
Algernon NeuroScience has filed a Form 1-A with the SEC, though the offering hasn't been qualified or declared effective yet. The company plans to use the proceeds to advance its R&D initiatives. Both companies' CEOs expressed positive sentiment about the collaboration, with Martin Kay from Netcapital and Christopher J. Moreau from Algernon commenting on the partnership.
The press release emphasizes that no securities can be sold before SEC qualification, and the announcement is purely informational. Investment risks are highlighted, including the speculative and illiquid nature of early-stage company investments, with potential for complete capital loss.
Netcapital Inc. (NASDAQ: NCPL) ha annunciato che la sua controllata, Netcapital Securities, fornirà servizi di broker-dealer e amministrativi per l'offerta di Regolamento A pianificata da Algernon NeuroScience. L'annuncio, fatto il 7 marzo 2025, esclude i servizi di sottoscrizione e di agente di collocamento.
Algernon NeuroScience ha presentato un modulo 1-A alla SEC, anche se l'offerta non è stata ancora qualificata o dichiarata efficace. L'azienda prevede di utilizzare i proventi per avanzare le proprie iniziative di ricerca e sviluppo. I CEO di entrambe le aziende hanno espresso sentimenti positivi riguardo alla collaborazione, con Martin Kay di Netcapital e Christopher J. Moreau di Algernon che hanno commentato il partenariato.
Il comunicato stampa sottolinea che nessun titolo può essere venduto prima della qualificazione della SEC e che l'annuncio è puramente informativo. Vengono evidenziati i rischi di investimento, inclusa la natura speculativa e illiquida degli investimenti in aziende in fase iniziale, con la possibilità di una perdita totale di capitale.
Netcapital Inc. (NASDAQ: NCPL) anunció que su filial, Netcapital Securities, proporcionará servicios de corredor y administrativos para la oferta de Regulación A planificada por Algernon NeuroScience. El anuncio, realizado el 7 de marzo de 2025, excluye los servicios de suscripción y agente de colocación.
Algernon NeuroScience ha presentado un Formulario 1-A ante la SEC, aunque la oferta aún no ha sido calificada ni declarada efectiva. La empresa planea utilizar los ingresos para avanzar en sus iniciativas de I+D. Los CEOs de ambas compañías expresaron sentimientos positivos sobre la colaboración, con Martin Kay de Netcapital y Christopher J. Moreau de Algernon comentando sobre la asociación.
El comunicado de prensa enfatiza que no se pueden vender valores antes de la calificación de la SEC, y que el anuncio es puramente informativo. Se destacan los riesgos de inversión, incluida la naturaleza especulativa e ilíquida de las inversiones en empresas en etapas tempranas, con la posibilidad de una pérdida total de capital.
넷캐피탈 주식회사 (NASDAQ: NCPL)는 자회사인 넷캐피탈 증권이 알저넌 뉴로사이언스의 계획된 규정 A 제공을 위한 중개인 및 관리 서비스를 제공할 것이라고 발표했습니다. 2025년 3월 7일에 발표된 이 내용은 인수 및 배치 대행 서비스는 제외됩니다.
알저넌 뉴로사이언스는 SEC에 1-A 양식을 제출했지만, 아직 이 제공은 승인되거나 유효하다고 선언되지 않았습니다. 회사는 수익금을 연구 개발 이니셔티브를 발전시키는 데 사용할 계획입니다. 두 회사의 CEO는 협력에 대해 긍정적인 감정을 표현했으며, 넷캐피탈의 마틴 케이와 알저넌의 크리스토퍼 J. 모로가 파트너십에 대해 언급했습니다.
보도 자료는 SEC의 자격 부여 전에 어떤 증권도 판매될 수 없으며, 이 발표는 순전히 정보 제공을 위한 것임을 강조합니다. 투자 위험이 강조되며, 초기 단계 기업 투자에서의 투기적이고 유동성이 없는 특성과 함께 자본 손실의 가능성이 있습니다.
Netcapital Inc. (NASDAQ: NCPL) a annoncé que sa filiale, Netcapital Securities, fournira des services de courtage et administratifs pour l'offre de Réglement A prévue par Algernon NeuroScience. L'annonce, faite le 7 mars 2025, exclut les services de souscription et d'agent de placement.
Algernon NeuroScience a déposé un formulaire 1-A auprès de la SEC, bien que l'offre n'ait pas encore été qualifiée ou déclarée efficace. L'entreprise prévoit d'utiliser les recettes pour faire progresser ses initiatives de R&D. Les PDG des deux entreprises ont exprimé des sentiments positifs concernant la collaboration, avec Martin Kay de Netcapital et Christopher J. Moreau d'Algernon commentant le partenariat.
Le communiqué de presse souligne qu'aucun titre ne peut être vendu avant la qualification par la SEC, et que l'annonce est purement informative. Les risques d'investissement sont mis en avant, y compris la nature spéculative et illiquide des investissements dans des entreprises en phase de démarrage, avec un potentiel de perte totale de capital.
Netcapital Inc. (NASDAQ: NCPL) gab bekannt, dass ihre Tochtergesellschaft, Netcapital Securities, Broker-Dealer- und Verwaltungsdienste für das geplante Regulierungsangebot A von Algernon NeuroScience bereitstellen wird. Die Ankündigung, die am 7. März 2025 gemacht wurde, schließt Underwriting- und Platzierungsdienste aus.
Algernon NeuroScience hat ein Formular 1-A bei der SEC eingereicht, obwohl das Angebot noch nicht qualifiziert oder für wirksam erklärt wurde. Das Unternehmen plant, die Einnahmen zur Förderung seiner F&E-Initiativen zu verwenden. Die CEOs beider Unternehmen äußerten sich positiv über die Zusammenarbeit, wobei Martin Kay von Netcapital und Christopher J. Moreau von Algernon über die Partnerschaft kommentierten.
Die Pressemitteilung betont, dass keine Wertpapiere vor der Qualifizierung durch die SEC verkauft werden können und dass die Ankündigung rein informativ ist. Die Investitionsrisiken werden hervorgehoben, einschließlich der spekulativen und illiquiden Natur von Investitionen in Unternehmen in der Frühphase, mit der Möglichkeit eines vollständigen Kapitalverlusts.
- None.
- None.
BOSTON, MA, March 07, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ: NCPL, NCPLW), a digital private capital markets ecosystem, today announced that its subsidiary, Netcapital Securities Inc. (“Netcapital Securities”), a FINRA-registered broker-dealer, has been engaged by Algernon NeuroScience Inc. (“Algernon NeuroScience”) for its planned Regulation A (Reg A) offering. Netcapital Securities plans to provide broker-dealer and administrative services, excluding underwriting and placement agent services, in connection with this offering.
Algernon NeuroScience has filed a Form 1-A with the U.S. Securities and Exchange Commission (SEC), though the offering has not yet been qualified or declared effective by the SEC. Algernon intends to use proceeds from the offering to advance its R&D initiatives.
“We are pleased that Algernon NeuroScience has selected Netcapital Securities as its broker-dealer to provide critical compliance and operational support for this offering,” said Martin Kay, CEO at Netcapital Inc.
“We look forward to working with the team at Netcapital Securities as we advance through the SEC qualification process for our planned Reg A offering,” said Christopher J. Moreau, CEO of Algernon NeuroScience.
The securities referenced in the planned Reg A offering may not be sold, nor may offers to buy be accepted, before the offering statement filed with the SEC is qualified. This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any offers, solicitations, or sales of securities will be made only by means of an offering circular that meets the requirements of Regulation A.
No money or other consideration is being solicited at this time, and if sent in response, it will not be accepted. There is no assurance that the SEC will qualify the offering or that Algernon NeuroScience will successfully raise capital. Investing in early-stage companies involves significant risks, and prospective investors should carefully review all offering materials and risk disclosures before making an investment decision. An investment in this private placement offering is speculative, illiquid, and involves a high degree of risk, including the potential loss of your entire investment.
About Netcapital Inc.
Netcapital Inc. is a fintech company with a scalable technology platform that allows private companies to raise capital online and provides private equity investment opportunities to investors. The Company's consulting group, Netcapital Advisors, provides marketing and strategic advice and takes equity positions in select companies. The Company’s funding portal, Netcapital Funding Portal, Inc., is registered with the SEC and is a member of the Financial Industry Regulatory Authority (“FINRA”), a registered national securities association. The Company’s broker-dealer, Netcapital Securities Inc., is also registered with the SEC and is a member of FINRA.
About Algernon NeuroScience Inc.
Algernon NeuroScience is a wholly-owned private subsidiary of Algernon Pharmaceuticals and has been established to advance its psychedelic DMT program for stroke and traumatic brain injury (TBI).
For more information, visit https://algernonneuroscience.com/.
Forward-Looking Statements
The information contained herein includes forward-looking statements. These statements relate to future events, including, but not limited to, statements relating to closing of the offering and satisfaction of closing conditions of the offering, the expected gross proceeds from the offering and statements regarding the anticipated use of proceeds from the offering, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Investor Contact
800-460-0815
ir@netcapital.com
FAQ
What services will Netcapital (NCPL) provide for Algernon NeuroScience's Reg A offering?
When did Netcapital (NCPL) announce the Algernon NeuroScience partnership?
What is the current status of Algernon NeuroScience's Reg A offering with Netcapital (NCPL)?
How will Algernon NeuroScience use the proceeds from the Reg A offering through Netcapital (NCPL)?
What are the key risks associated with the Algernon NeuroScience offering on Netcapital (NCPL)?
